3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
2
Sarcoma
1
NET
1
Endocrine
1
Conditions
Sarcoma
4
Neuroectodermal Tumors, Primitive
1
Gastrointestinal Stromal Tumors
1
Interventions
Magnetic Resonance Spectroscopy
6
Temozolomide
4
Radiotherapy
3
Cyclophosphamide
3
Carmustine
3
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
3
sargramostim
2
aldesleukin
2
Thalidomide
2
Paclitaxel
2
Gadolinium DTPA
2
Filgrastim
2
Donepezil
2
Biopsy
2
temsirolimus
1
surufatinib
1
plerixafor
1
omburtamab I-131
1
ganitumab
1
gallium Ga 68 dotatate
1
gadobutrol
1
gadobenic acid
1
entinostat
1
cixutumumab
1
carboxyamido-triazole
1
azurin (50-77)
1
antineoplaston AS 2-1
1
antineoplaston A10
1
adavosertib
1
Zoledronic Acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neuroectodermal Tumors, Primitive
×
TH 302
×
Sarcoma
×
Clear all
NCT01381822
2014-04-21
TH-CR-410
Threshold Pharmaceuticals
Phase 1
Unknown
58 enrolled